Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regenerative Research Foundation is currently prosecuting 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is assigned to ROBINSON, HOPE A, who serves as the busiest examiner for the company. The entire pending workload is currently under this individual's review, which suggests that the company's intellectual property strategy is focused on a specific technical path.
The administrative profile shows 1 distinct examiner and 1 distinct art unit involved in the process. The 1 distinct art unit indicates that the technical claims are being evaluated within a specific division of the patent office. For a practitioner, this means the prosecution strategy is centered on the requirements of this division rather than multiple units. The 1 distinct examiner represents the total number of officials currently reviewing the company's applications.
With ROBINSON, HOPE A handling 1 busiest examiner pending office action, the company's success is tied to the discretion of this individual. Practitioners should monitor the 1 pending office action to understand the specific hurdles being raised in the Biotechnology & Pharmaceuticals sector. The results of this prosecution will define the company's immediate path within the patent office's administrative framework.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036592 | Compositions and Methods for Controlled Protein Degradation in Neurodegenerative Disease | ROBINSON, HOPE A | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036592 | Compositions and Methods for Controlled Protein Degradation in Neurodegenerative Disease | ROBINSON, HOPE A | 1652 | §112 | Final Rejection | 22d overdue | Pending | May 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenerative Research Foundation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hope A Robinson has the most, with 1 of Regenerative Research Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.